PMID- 32783408
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20201105
IS  - 1899-5276 (Print)
IS  - 1899-5276 (Linking)
VI  - 29
IP  - 8
DP  - 2020 Aug
TI  - Clinical outcomes of continuous vs intermittent meropenem infusion for the 
      treatment of sepsis: A systematic review and meta-analysis.
PG  - 993-1000
LID - 10.17219/acem/121934 [doi]
AB  - The antibiotic meropenem is commonly administered to patients with sepsis and 
      septic shock. The aim of this study was to conduct a meta-analysis to evaluate 
      the clinical efficacy and safety of continuous compared to intermittent meropenem 
      infusion for the treatment of sepsis. Electronic databases such as PubMed, 
      EMBASE, Cochrane Library, and China National Knowledge Infrastructure (CNKI) were 
      researched to collect clinical trials comparing continuous and intermittent 
      infusion of meropenem in patients with sepsis. After data extraction and quality 
      assessment of the included studies, Stata v. 12.0 software (Stata Corporation 
      LLC, College Station, USA) was used for a meta-analysis of mortality, clinical 
      cure, microbiological eradication, and safety. Seven studies with a total of 
      1,191 participants met the inclusion criteria and were included in the 
      meta-analysis. The meta-analysis showed that continuous meropenem infusion was 
      superior to intermittent infusion in terms of mortality (combined risk ratio (RR) 
      = 0.66, 95% confidence interval (95% CI) = 0.46-0.98, p = 0.03), clinical cure 
      rate (combined RR = 1.15, 95% CI = 1.02-1.30, p = 0.026) and microbiological 
      eradication (combined RR = 1.20, 95% CI = 1.01-1.42, p = 0.04), although it may 
      increase the incidence of some adverse events (AEs). Compared with intermittent 
      dosing, administration of meropenem antibiotics through continuous infusion in 
      patients with sepsis is associated with decreased hospital mortality, increased 
      clinical cure rates and greater microbiological eradication. Further high-quality 
      studies should be conducted to confirm our findings.
FAU - Chen, Peng
AU  - Chen P
AD  - Department of Pharmacy, Renmin Hospital of Wuhan University, China.
FAU - Chen, Fuchao
AU  - Chen F
AD  - Department of Pharmacy, Dongfeng Hospital, Hubei University of Medicine, Shiyan, 
      China.
FAU - Lei, Jiexin
AU  - Lei J
AD  - Department of Endocrinology, Renmin Hospital of Wuhan University, China.
FAU - Zhou, Benhong
AU  - Zhou B
AD  - Department of Pharmacy, Renmin Hospital of Wuhan University, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - Poland
TA  - Adv Clin Exp Med
JT  - Advances in clinical and experimental medicine : official organ Wroclaw Medical 
      University
JID - 101138582
RN  - 0 (Anti-Bacterial Agents)
RN  - FV9J3JU8B1 (Meropenem)
SB  - IM
MH  - Anti-Bacterial Agents/adverse effects
MH  - China
MH  - Humans
MH  - Infusions, Intravenous
MH  - Meropenem/*therapeutic use
MH  - *Sepsis/drug therapy
OTO - NOTNLM
OT  - continuous infusion
OT  - meropenem
OT  - sepsis
EDAT- 2020/08/13 06:00
MHDA- 2020/11/06 06:00
CRDT- 2020/08/13 06:00
PHST- 2020/08/13 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
PHST- 2020/08/13 06:00 [entrez]
AID - 10.17219/acem/121934 [doi]
PST - ppublish
SO  - Adv Clin Exp Med. 2020 Aug;29(8):993-1000. doi: 10.17219/acem/121934.